Inclusion Criteria:

- A signed informed consent document.

- Male and non-pregnant, non-lactating female subjects.

- Female subjects must be post menopausal, surgically sterile, or practicing an
effective method of birth control and continue to do so throughout the trial.

- At least 18 years of age.

- Have chronic malignant tumor-related pain

- Are opioid-naïve or have been pretreated with an equianalgesic dose range equivalent
of up to 160 mg oral morphine per day and are dissatisfied with prior treatment.

- Have a mean pain intensity of at least 5 points on an 11-point Numeric Rating Scale
(where 0 indicates no pain and 10 indicates worst possible pain).

- Have an expected course of the disease such that the pain that will permit compliance
with the trial protocol over the entire trial period.

Exclusion Criteria:

- Have a life-long history of seizure disorder or epilepsy.

- Have had any of the following within one year: mild/moderate traumatic brain injury,
stroke, and transient ischemic attack.

- Have had severe traumatic brain injury within 15 years (consisting of ≥ 1 of the
following: brain contusion, intracranial hematoma, and either unconsciousness or
post-traumatic amnesia lasting for more than 24 hours) or residual sequelae
suggesting transient changes in consciousness.

- Have a known history and/or presence of cerebral metastases.

- Have moderately or severely impaired hepatic function.

- Have laboratory values reflecting inadequate hepatic function.

- Have thrombopenia, leucopenia or hypercalcemia

- Have severely impaired renal function.

- Having uncontrolled hypertension

- Having clinically relevant history of hypersensitivity, allergy or contraindications
to morphine or any of the excipients.

- Have chronic hepatitis B or hepatitis C, or Human Immunodeficiency Virus (HIV).

- Subjects currently undergoing the following concomitant therapy: radiotherapy, pain
inducing chemotherapy, anti-parkinsonian drugs, neuroleptics, monoamine oxidase
inhibitors, serotonin norepinephrine re-uptake inhibitors (SNRI) or any other
analgesic therapy than investigational medication or rescue medication during the
trial. Selective serotonin re-uptake inhibitor (SSRI) treatments are allowed if taken
for at least 30 days before the screening period of the trial at an unchanged dose.